{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:55:39Z","timestamp":1793501739687,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jceh.2021.09.010","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T21:45:01Z","timestamp":1631742301000},"page":"560-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist"],"prefix":"10.1016","volume":"12","author":[{"given":"Pankaj","family":"Puri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Kotwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2021.09.010_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/01.mcg.0000190774.91875.d2","article-title":"Liver disease in patients with diabetes mellitus","volume":"40","author":"Harrison","year":"2006","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2337\/diacare.22.5.756","article-title":"Cause-specific mortality in type 2 diabetes. The verona diabetes study","volume":"22","author":"de Marco","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib3","first-page":"119","article-title":"Prognostic significance of diabetes in patients with cirrhosis","volume":"20","author":"Bianchi","year":"1994","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2021.09.010_bib4","first-page":"S1","article-title":"Standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1665-2681(19)31805-8","article-title":"Hepatogenous diabetes. Current views of an ancient problem","volume":"8","author":"Garc\u00eda Compean","year":"2009","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib6","doi-asserted-by":"crossref","first-page":"e3157","DOI":"10.1002\/dmrr.3157","article-title":"Prevalence of diabetes in liver cirrhosis: a systematic review and meta-analysis","volume":"35","author":"Lee","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jceh.2021.09.010_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2337\/dc06-1539","article-title":"Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease","volume":"30","author":"Tolman","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/oxfordjournals.epirev.a000808","article-title":"Association between hepatitis C virus infection and diabetes mellitus","volume":"23","author":"Mehta","year":"2001","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.jceh.2021.09.010_bib9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1464-5491.1992.tb01881.x","article-title":"Prevalence of haemochromatosis amongst patients with diabetes mellitus","volume":"9","author":"Singh","year":"1992","journal-title":"Diabet Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/hep.21208","article-title":"Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection","volume":"43","author":"Lai","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib11","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.3748\/wjg.v17.i48.5240","article-title":"Impact of liver diseases on the development of type 2 diabetes mellitus","volume":"17","author":"Hsieh","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/jhep.2002.30692","article-title":"NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome","volume":"35","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MOL.0b013e32834c7cfc","article-title":"Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic","volume":"22","author":"Schattenberg","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jceh.2021.09.010_bib14","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jhep.2015.08.011","article-title":"Contribution of \u03b2-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease","volume":"63","author":"Grancini","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40618-016-0451-7","article-title":"Endocrine dysfunction in hereditary hemochromatosis","volume":"39","author":"Pelusi","year":"2016","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.jceh.2021.09.010_bib16","doi-asserted-by":"crossref","first-page":"746.e1","DOI":"10.1016\/j.amjmed.2016.12.029","article-title":"Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome","volume":"130","author":"Kasmari","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.biopha.2018.06.095","article-title":"Diabetes and hepatocellular carcinoma: a pathophysiological link and pharmacological management","volume":"106","author":"Singh","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jceh.2021.09.010_bib18","doi-asserted-by":"crossref","first-page":"E1170","DOI":"10.1210\/jc.2012-1162","article-title":"Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus","volume":"97","author":"Chang","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jceh.2021.09.010_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/00365521.2012.719926","article-title":"Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis","volume":"48","author":"Zhang","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jhep.2017.10.018","article-title":"Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study","volume":"68","author":"Kim","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ajg.2018.08.003","article-title":"Managing diabetes and liver disease association","volume":"19","author":"Hamed","year":"2018","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/ijem.IJEM_512_16","article-title":"Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment","volume":"21","author":"Gangopadhyay","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jceh.2021.09.010_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trsl.2009.04.002","article-title":"Estimation of red blood cell lifespan from alveolar carbon monoxide measurements","volume":"154","author":"Krishnan","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.jceh.2021.09.010_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13300-017-0362-4","article-title":"Utility and limitations of glycated hemoglobin (HbA1c) in patients with liver cirrhosis as compared with oral glucose tolerance test for diagnosis of diabetes","volume":"9","author":"Sehrawat","year":"2018","journal-title":"Diabetes Ther"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2021.09.010_bib25","first-page":"S168","article-title":"12. Older adults: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4254\/wjh.v3.i5.99","article-title":"Insulin resistance and chronic liver disease","volume":"3","author":"Kawaguchi","year":"2011","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib27","first-page":"70","article-title":"Management of diabetes during fasting and feasting in India","volume":"67","author":"Saboo","year":"2019","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.jceh.2021.09.010_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","article-title":"Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis","volume":"47","author":"Edginton","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2021.09.010_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00003088-200544020-00004","article-title":"The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance","volume":"44","author":"Le Couteur","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2021.09.010_bib30","first-page":"1","article-title":"Managing diabetes and liver disease association, guidelines (consensus) development","volume":"3","author":"Hamed","year":"2015","journal-title":"J\u00a0Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jceh.2021.09.010_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3748\/wjg.v22.i1.72","article-title":"Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance","volume":"22","author":"Dietrich","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib32","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.26338","article-title":"Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications","volume":"58","author":"Garcia-Martinez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","article-title":"Dose adjustment in patients with liver disease","volume":"28","author":"Delc\u00f2","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.jceh.2021.09.010_bib34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.4103\/ijem.IJEM_79_18","article-title":"Hepatogenous diabetes: an underestimated problem of liver cirrhosis","volume":"22","author":"Kumar","year":"2018","journal-title":"Indian J Endocr Metab"},{"key":"10.1016\/j.jceh.2021.09.010_bib35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.12324","article-title":"Review article: prescribing medications in patients with cirrhosis \u2013 a practical guide","volume":"37","author":"Lewis","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2021.09.010_bib36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.13105\/wjma.v7.i8.380","article-title":"Antidiabetic agents in patients with hepatic impairment","volume":"7","author":"Papazafiropoulou","year":"2019","journal-title":"World J Meta-Anal"},{"key":"10.1016\/j.jceh.2021.09.010_bib37","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.semnephrol.2006.11.001","article-title":"Acid-base and potassium disorders in liver disease","volume":"26","author":"Ahya","year":"2006","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jceh.2021.09.010_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jceh.2021.09.010_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF02900711","article-title":"Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis","volume":"20","author":"Trenti","year":"1990","journal-title":"Ric Clin Lab"},{"key":"10.1016\/j.jceh.2021.09.010_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195028","article-title":"Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring","volume":"13","author":"Honda","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2021.09.010_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cld.2011.12.009","article-title":"Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses","volume":"16","author":"Periyalwar","year":"2012","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2021.09.010_bib42","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/hep.26716","article-title":"Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study","volume":"59","author":"Hong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib43","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/hep.25548","article-title":"Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease","volume":"55","author":"Sullivan","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib44","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib45","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1053\/j.gastro.2016.03.004","article-title":"Perspectives on treatment for nonalcoholic steatohepatitis","volume":"150","author":"Lassailly","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.09.010_bib46","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.3748\/wjg.v20.i15.4382","article-title":"Effect of resistance training on nonalcoholic fatty-liver disease a randomized-clinical trial","volume":"20","author":"Zelber-Sagi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib47","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.09.010_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0261-5614(89)90008-3","article-title":"Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake","volume":"8","author":"Swart","year":"1989","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jceh.2021.09.010_bib49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3945\/ajcn.2010.29211","article-title":"Breakfast improves cognitive function in cirrhotic patients with cognitive impairment","volume":"92","author":"Vaisman","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jceh.2021.09.010_bib50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.22367","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jceh.2020.09.003","article-title":"Nutrition in chronic liver disease: consensus statement of the Indian national association for study of the liver","volume":"11","author":"Puri","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib52","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jhep.2016.07.040","article-title":"Sarcopenia from mechanism to diagnosis and treatment in liver disease","volume":"65","author":"Dasarathy","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.soard.2012.07.021","article-title":"Bariatric surgery in patients with liver cirrhosis","volume":"9","author":"Shimizu","year":"2013","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jceh.2021.09.010_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12664-016-0643-2","article-title":"Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation","volume":"35","author":"Choudhary","year":"2016","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib55","doi-asserted-by":"crossref","first-page":"780","DOI":"10.5604\/16652681.1171746","article-title":"The treatment of diabetes mellitus of patients with chronic liver disease","volume":"14","author":"Garc\u00eda-Compe\u00e1n","year":"2015","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib56","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/qjmed\/hcg049","article-title":"Metformin associated lactic acidosis in a patient with liver disease","volume":"96","author":"Edwards","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.jceh.2021.09.010_bib57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199801223380415","article-title":"Lactic acidosis in patients with diabetes treated with metformin","volume":"338","author":"Misbin","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib58","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/dme.12515","article-title":"A\u00a0justification for less restrictive guidelines on the use of metformin in stable chronic renal failure","volume":"31","author":"Adam","year":"2014","journal-title":"Diabet Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/apt.15635","article-title":"The safety and pharmacokinetics of metformin in patients with chronic liver disease","volume":"51","author":"Smith","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2021.09.010_bib60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.15331","article-title":"Long-term metformin use may improve clinical outcomes in diabetic patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"50","author":"Vilar-Gomez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2021.09.010_bib61","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib62","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/jc.2010-2415","article-title":"Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients","volume":"96","author":"Nkontchou","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jceh.2021.09.010_bib63","doi-asserted-by":"crossref","first-page":"e6888","DOI":"10.1097\/MD.0000000000006888","article-title":"Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients","volume":"96","author":"Ma","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jceh.2021.09.010_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049279","article-title":"Metformin inhibits glutaminase activity and protects against hepatic encephalopathy","volume":"7","author":"Ampuero","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2021.09.010_bib65","article-title":"Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis","author":"Yen","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jceh.2021.09.010_bib66","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/M15-0308","article-title":"Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus","volume":"163","author":"Ou","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib67","first-page":"681","article-title":"An analysis of the effect of hypoalbuminemia on the amount of free drug in plasma for drugs bound at two sets of sites","volume":"9","author":"Wosilait","year":"1974","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1016\/j.jceh.2021.09.010_bib68","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00000441-196412000-00004","article-title":"Disappearance rate of metabolism of Tolbutamide in test subjects with liver disease or with impaired renal function","volume":"248","author":"Nelson","year":"1964","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jceh.2021.09.010_bib69","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2337\/diab.12.5.414","article-title":"Disappearance rate of Tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis and renal disease","volume":"12","author":"Ueda","year":"1963","journal-title":"Diabetes"},{"key":"10.1016\/j.jceh.2021.09.010_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243783","article-title":"Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis","volume":"15","author":"Yen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2021.09.010_bib71","first-page":"721","article-title":"Chlorpropamide hepatotoxicity: report of a case and review of the literature","volume":"79","author":"Schneider","year":"1984","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib72","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7326\/0003-4819-106-6-837","article-title":"Glyburide-induced hepatitis","volume":"106","author":"Goodman","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib73","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2005.02.011","article-title":"Cholestatic liver injury after glimepiride therapy","volume":"42","author":"Chounta","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib74","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00042737-200012010-00021","article-title":"Gliclazide-induced acute hepatitis","volume":"12","author":"Dourakis","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib75","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1478-3231.2009.02191.x","article-title":"Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection","volume":"30","author":"Kawaguchi","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.09.010_bib76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/00912700022008793","article-title":"Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease","volume":"40","author":"Hatorp","year":"2000","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jceh.2021.09.010_bib77","first-page":"634","article-title":"Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis","volume":"40","author":"Choudhury","year":"2000","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jceh.2021.09.010_bib78","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2337\/diacare.28.3.752-a","article-title":"Cholestatic hepatitis associated with repaglinide","volume":"28","author":"L\u00f3pez-Garc\u00eda","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib79","doi-asserted-by":"crossref","first-page":"823","DOI":"10.7326\/0003-4819-141-10-200411160-00024","article-title":"Acute hepatotoxicity caused by repaglinide","volume":"141","author":"Nan","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib80","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2337\/diacare.22.9.1568","article-title":"Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes","volume":"22","author":"Scheen","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib81","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.20567","article-title":"Troglitazone and liver injury: in search of answers","volume":"41","author":"Chojkier","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib82","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00002018-200124120-00002","article-title":"Hepatotoxicity with thiazolidinediones: is it a class effect?","volume":"24","author":"Scheen","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.jceh.2021.09.010_bib83","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/0003-4819-136-6-200203190-00008","article-title":"Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy","volume":"136","author":"May","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Metaanalysis: pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2021.09.010_bib85","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.13856","article-title":"The asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 2: management and special groups","volume":"33","author":"Chitturi","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib86","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib87","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib88","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","article-title":"Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis","volume":"180","author":"Loke","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.jceh.2021.09.010_bib89","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/liv.14714","article-title":"Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis","volume":"41","author":"Yen","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.09.010_bib90","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.09.010_bib91","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3748\/wjg.v19.i15.2298","article-title":"Dipeptidyl peptidase-4: a key player in chronic liver disease","volume":"19","author":"Itou","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2957","article-title":"Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes","volume":"34","author":"Bouchi","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jceh.2021.09.010_bib93","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/11584350-000000000-00000","article-title":"Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin","volume":"50","author":"Boulton","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2021.09.010_bib94","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/DMSO.S106133","article-title":"Teneligliptin in management of type 2 diabetes mellitus","volume":"9","author":"Sharma","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jceh.2021.09.010_bib95","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40265-019-01086-0","article-title":"The unique pharmacological and pharmacokinetic profile of Teneligliptin: implications for clinical practice","volume":"79","author":"Ceriello","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jceh.2021.09.010_bib96","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12020-014-0179-0","article-title":"Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature","volume":"46","author":"Giorda","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.jceh.2021.09.010_bib97","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2012.04173.x","article-title":"Pharmacokinetics of linagliptin in subjects with hepatic impairment","volume":"74","author":"Graefe-Mody","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jceh.2021.09.010_bib98","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40262-014-0157-y","article-title":"Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2021.09.010_bib99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1463-1326.2010.01214.x","article-title":"An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials","volume":"12","author":"Ligueros-Saylan","year":"2010","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.jceh.2021.09.010_bib100","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1210\/jc.2008-1296","article-title":"Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides","volume":"94","author":"Abu-Hamdah","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jceh.2021.09.010_bib101","doi-asserted-by":"crossref","first-page":"R200","DOI":"10.1530\/EC-21-0130","article-title":"How glucagon-like peptide 1 receptor agonists work","volume":"10","author":"Andreasen","year":"2021","journal-title":"Endocr Connect"},{"key":"10.1016\/j.jceh.2021.09.010_bib102","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicenter, double-blind randomized, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.09.010_bib103","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib104","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03762.x","article-title":"Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide","volume":"70","author":"Flint","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jceh.2021.09.010_bib105","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s13300-019-0669-4","article-title":"Consensus recommendations on GLP-1 RA use in the management of type 2 diabetes mellitus: south asian task force","volume":"10","author":"Kalra","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jceh.2021.09.010_bib106","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jceh.2021.09.010_bib107","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2021.09.010_bib108","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.31270","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib109","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.31399","article-title":"Letter to the editor: sodium-glucose cotransporter-2 inhibitors are not the magic pills for control of ascites in cirrhosis and diabetes","volume":"73","author":"Kumar","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.09.010_bib110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites","volume":"11","author":"Saffo","year":"2018","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"10.1016\/j.jceh.2021.09.010_bib111","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.clinthera.2011.09.011","article-title":"Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study","volume":"33","author":"Kasichayanula","year":"2011","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.jceh.2021.09.010_bib112","first-page":"9","article-title":"Acarbose for diabetes mellitus","volume":"38","year":"1996","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.jceh.2021.09.010_bib113","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/17425255.2014.902444","article-title":"Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease","volume":"10","author":"Scheen","year":"2014","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.jceh.2021.09.010_bib114","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0168-8278(99)80039-7","article-title":"Impaired splanchnic and peripheral glucose uptake in liver cirrhosis","volume":"31","author":"Imano","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4254\/wjh.v12.i9.533","article-title":"Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases","volume":"12","author":"Chung","year":"2020","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib116","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1542-3565(04)00667-6","article-title":"A\u00a0randomized controlled trial of acarbose in hepatic encephalopathy","volume":"3","author":"Gentile","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib117","first-page":"282","article-title":"Hepatitis aguda por acarbosa. Descripci\u00f3n de 2 episodios en una misma paciente [Acarbose-induced acute hepatitis. Report of two events in the same patient]","volume":"23","author":"de la Vega","year":"2000","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib118","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1572-0241.1998.481_1.x","article-title":"Acarbose-induced acute hepatitis","volume":"93","author":"Diaz-Gutierrez","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib119","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0140-6736(05)60134-1","article-title":"Acarbose-induced acute severe hepatotoxicity","volume":"349","author":"Carrascosa","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.09.010_bib120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1463-1326.2001.00103.x","article-title":"Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis","volume":"3","author":"Gentile","year":"2001","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.jceh.2021.09.010_bib121","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1463-1326.2007.00802.x","article-title":"Insulin therapy in renal disease","volume":"10","author":"Iglesias","year":"2008","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.jceh.2021.09.010_bib122","unstructured":"Indian Council of Medical Research (ICMR) guidelines for management of type 2 diabetes 2018. Available from: https:\/\/main.icmr.nic.in\/sites\/default\/files\/guidelines\/ICMR_GuidelinesType2diabetes2018_0.pdf. [Last accessed on 21 Aug 2021]."},{"key":"10.1016\/j.jceh.2021.09.010_bib123","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12876-021-01773-x","article-title":"Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?","volume":"21","author":"Yen","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4140\/TCP.n.2017.105","article-title":"Sliding-scale insulin use in long-term care: an updated perspective","volume":"32","author":"Woods","year":"2017","journal-title":"Consult Pharm"},{"key":"10.1016\/j.jceh.2021.09.010_bib125","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2012.07.2574","article-title":"Managing diabetes in patients with chronic liver disease","volume":"124","author":"Khan","year":"2012","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jceh.2021.09.010_bib126","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1038\/ctg.2015.31","article-title":"Inclusion of sarcopenia within MELD (MELD Sarcopenia) and the prediction of mortality in patients with cirrhosis","volume":"6","author":"Montano-Loza","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jceh.2021.09.010_bib127","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jhep.2017.11.030","article-title":"A\u00a0model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort","volume":"68","author":"van Vugt","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib128","article-title":"Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2021.09.010_bib129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cgh.2011.08.028","article-title":"Muscle wasting is associated with mortality in patients with cirrhosis","volume":"10","author":"Montano-Loza","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.09.010_bib130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1573399810666140918121022","article-title":"Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II","volume":"10","author":"Cetrone","year":"2014","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jceh.2021.09.010_bib131","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/DMSO.S186600","article-title":"Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship","volume":"12","author":"Mesinovic","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jceh.2021.09.010_bib132","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.jceh.2021.09.010_bib133","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm493244.htm. [Last accessed 21 Aug 2021]."},{"key":"10.1016\/j.jceh.2021.09.010_bib134","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.phrs.2019.01.042","article-title":"Management of diabetes mellitus in patients undergoing liver transplantation","volume":"141","author":"Grancini","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jceh.2021.09.010_bib135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s13300-018-0374-8","article-title":"Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment","volume":"9","author":"Pel\u00e1ez-Jaramillo","year":"2018","journal-title":"Diabetes Ther"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688321002462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688321002462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:08:01Z","timestamp":1760854081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688321002462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0973688321002462"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2021.09.010","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2021.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}